Citi reiterates buy rating on Nektar Therapeutics with $151 target
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
| (NASDAQ: KYMR) | Delayed: 108.35 +2.37 (2.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $105.98 | 52 Week High | $ | |||
| Open | $104.58 | 52 Week Low | $ | |||
| Day High | $108.68 | P/E | N/A | |||
| Day Low | $103.45 | EPS | $ | |||
| Volume | 1,167,391 | |||||
| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 40.26 +0.35 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.91 | 52 Week High | $19.98 | |||
| Open | $39.22 | 52 Week Low | $10.52 | |||
| Day High | $40.35 | P/E | N/A | |||
| Day Low | $38.45 | EPS | $-1.45 | |||
| Volume | 1,510,055 | |||||
